Research: Design, Synthesis, Purification and Analytical Characterization of Small Epigenetic (and not) Modulators
THEMATIC AREA: Drug Design and Development
SSD: CHIM/08
Chiara Lambona graduated with honors in Drug Chemistry and Technology in October 2022 under the supervision of Prof.ssa Rossella Fioravanti with a Thesis in Pharmaceutical Chemistry entitled "Design, Synthesis and Biological Evaluation of New Dual Selective Hybrid Inhibitors of HDAC1,2/LSD1 as a New Epi-Pharmacological Approach to Fight Cancer". During her studies, she won two fellowships held at the laboratories of Analysis of Medicines II and Chemical Analysis Pharmaceutical and Toxicological II. She also won the Path of Excellence.
From January 2023, she continued her research activity as research fellow under the supervision of Prof. Sergio Valente and Prof. Antonello Mai working on the design and synthesis of new inhibitors of NADPH oxidase. In November 2023, he began the PhD course in Life Sciences under the supervision of Prof. Sergio Valente and Prof. Antonello Mai working on the development of new epigenetic modulators (and not).
The research activity is based on the design of molecules of potential pharmaceutical interest in the field of epigenetics and not. The aim is to develop molecules that can modulate the activity of different epigenetic targets, such as HDACs, LSD1, EZH2 and DNMTs. In addition, the design is aimed at obtaining hybrid molecules that simultaneously modulate two targets, given the advantages of polypharmacology compared to single-target therapy. The molecules will be synthesized, purified and characterized analytically through the study of nuclear magnetic resonance (1H-NMR and 13C-NMR) and mass spectrometry. The results will be evaluated following the biochemical and biological tests performed by collaborators.
SEMINARS, MEETINGS, COURSES
02-06/07/2023 (Urbino) - ESMEC 2023 - European School of Medicinal Chemistry (42° Ed.)
Poster presentation entitles "DESIGN, SYNTHESIS AND ANTICANCER ACTIVITY OF NOVEL DUAL HDAC1,2/LSD1 INHIBITORS"
17-20/09/2023 (Chieti) - XXVIII National Meeting on Medicinal Chemistry (NMMC28)
Oral communication entitled "TARGETING ROS PRODUCTION THROUGH INHIBITION OF NADPH OXIDASE".